The Food and Drug Administration (the “FDA”) has approved a modification to the Mifepristone Risk Evaluation and Mitigation Strategy (“REMS”) Program, increasing the accessibility of.
The FDA approved a modification to the Mifepristone Risk Evaluation and Mitigation Strategy, REMS, Program. The FDA’s approval of commercial dispensing of mifepristone likely will not change the current practice of prescribing and dispensing mifepristone for abortion.